ONO-LB-457: a novel and orally active leukotriene B4 receptor antagonist.
Kishikawa
K
K
Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Matsunaga
N
N
Maruyama
T
T
Seo
R
R
Toda
M
M
Miyamoto
T
T
Kawasaki
A
A
D000818:Animals; D001667:Binding, Competitive; D002449:Cell Aggregation / Q000187:drug effects; D006168:Guinea Pigs; D006801:Humans; D007975:Leukotriene B4 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008168:Lung; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D009503:Neutropenia / Q000139:chemically induced; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism; D010666:Phenylpropionates / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D011971:Receptors, Immunologic / Q000187:drug effects* / Q000378:metabolism; D018102:Receptors, Leukotriene B4; D012867:Skin / Q000187:drug effects
D010666:Phenylpropionates; D011971:Receptors, Immunologic; D018102:Receptors, Leukotriene B4; C067523:ONO-LB 457; D007975:Leukotriene B4; D009195:Peroxidase